Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04862663
Title Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Capivasertib + Fulvestrant + Palbociclib

Fulvestrant + Palbociclib

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.